Upcoming Events

CONFERENCES & CONGRESSES

September 15-17, 2023 | ACOG Section XI
Houston, TX

September 28-30, 2023 | ACOG Sections VIII & IX
Wailea, Maui, HI

September 28-29, 2023 | North American Menopause Society (NAMS)
Philadelphia, PA

October 12-14, 2023 | U.S. Women's Health Alliance Fall Conference (USWHA)
New York, NY

October 20-21, 2023 | ACOG Section II
Brooklyn, NY

October 20-22, 2023 | ACOG Section IV
Washington, DC

October 27-29, 2023 | ACOG Sections I and V
Newport, RI

October 29 – November 1, 2023 | Nurse Practitioners in Women's Health (NPWH)
San Diego, CA

Planning to attend? Email us to connect with the team: Maggie Stauber ([email protected])

REGIONAL EDUCATIONAL EVENTS

If you would like to participate in an upcoming Regional Educational Event, please email Maggie Stauber ([email protected])

September 21, 2023
Char Restaurant
431 S Highland St #120
Memphis, TN 38111
Register by September 19, 2023

ON DEMAND EVENTS

The Balancing Act: Management of Risk Assessment for Ovarian Cancer – Featuring Aspira's CEO, Nicole Sandford, and Axia's Dr. Gerard Reilly

PRECAUTION: OvaWatch is intended for use as a non-invasive test to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment (ICA) as indeterminate or benign.  In conjunction with imaging (ultrasound and/or CT) and clinical assessment, this test will support physicians in making informed clinical decisions in the management of women with adnexal masses. The test is not intended as a screening test or a stand-alone diagnostic assay. Ova1® and Overa® should not be used without an independent clinical and imaging evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

A Path to Equity: The Impact of Health Disparities in Ovarian Cancer Care

PRECAUTION: Ova1® and Overa® should not be used without an independent clinical and imaging evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Key Opinion Leader Webinar

Expert Consultation is available for those who have already ordered an OvaSuite test as part of the Aspira Women’s Health Suite of Services.